Clinic
MMC of Nevada LLC
MMC of Nevada LLC was paid $2.60M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoMMC OF NEVADA LLC
MESQUITE, NV 89027
MESQUITE, NV 89027
33aNPI1275588782assigned 05/23/2006
33bProvider typePhysical Therapy Clinic/Center
28Total paid$2.60M
24GClaims168,852
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Therapy Clinic/Center providers in Nevada
Rank by total paid#2 of 17
Median peer was paid$143K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,752 | $458K | |
| 2019 | 26,224 | $335K | |
| 2020 | 28,556 | $312K | |
| 2021 | 23,949 | $398K | |
| 2022 | 26,223 | $395K | |
| 2023 | 21,717 | $421K | |
| 2024incomplete | 16,431 | $285K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 8,323 | 5,938 | $813K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 6,217 | 5,325 | $396K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 1,801 | 924 | $393K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 4,249 | 2,668 | $352K |
| 80053 | Comprehensive metabolic panel | 7.3% | 16,138 | 10,982 | $189K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.1% | 1,284 | 885 | $158K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 1,501 | 1,409 | $63K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,619 | 1,264 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 458 | 404 | $19K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 268 | 233 | $19K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 865 | 822 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,489 | 1,273 | $13K |
93 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 721 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,490 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,093 | $10K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,879 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 90 | $9K |
| 80050 | General health panel | <1% | 219 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,449 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,335 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,098 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,617 | $6K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 30 | $5K |
| 87428 | <1% | 1,038 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 77 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 820 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,144 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,812 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,402 | $2K |
| 87088 | <1% | 1,944 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,311 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 585 | $2K |
| 85610 | <1% | 1,734 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 315 | $2K |
| 87400 | <1% | 738 | $2K | |
| 80061 | Lipid panel | <1% | 3,313 | $2K |
| 83880 | <1% | 655 | $1K | |
| 87077 | <1% | 855 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,926 | $1K |
| 84484 | <1% | 4,344 | $955.54 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,847 | $861.12 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 576 | $817.56 |
| 83690 | <1% | 4,533 | $801.39 | |
| 73562 | <1% | 65 | $783.08 | |
| 83735 | <1% | 4,212 | $750.26 | |
| 73630 | <1% | 47 | $741.56 | |
| 82607 | <1% | 483 | $740.91 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 223 | $708.58 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 90 | $696.37 |
| 81001 | <1% | 4,845 | $506.31 | |
| 83605 | <1% | 1,988 | $497.50 | |
| 96376 | <1% | 142 | $427.41 | |
| 85027 | <1% | 1,687 | $403.82 | |
| 81003 | <1% | 2,538 | $382.26 | |
| 81025 | <1% | 743 | $360.60 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 66 | $333.80 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,621 | $309.21 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 862 | $289.71 |
| 84703 | <1% | 1,256 | $239.54 | |
| 73030 | <1% | 27 | $207.66 | |
| 87186 | <1% | 1,021 | $153.14 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,834 | $150.69 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,077 | $131.00 |
| 87081 | <1% | 641 | $117.31 | |
| 86140 | <1% | 560 | $90.48 | |
| 84702 | <1% | 23 | $65.27 | |
| 84439 | <1% | 1,959 | $64.23 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,141 | $59.14 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 75 | $58.17 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 316 | $51.87 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14 | $48.12 |
| 83550 | <1% | 58 | $40.09 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 566 | $37.28 |
| 82550 | <1% | 93 | $36.40 | |
| 82746 | <1% | 313 | $31.40 | |
| 82728 | <1% | 51 | $23.28 | |
| 94760 | <1% | 162 | $19.44 | |
| 85652 | <1% | 639 | $17.04 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 219 | $16.40 |
| 86850 | <1% | 63 | $16.35 | |
| 87040 | <1% | 67 | $12.88 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 361 | $11.39 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $9.55 |
| 94761 | <1% | 113 | $9.02 | |
| 85730 | <1% | 155 | $8.20 | |
| 87420 | <1% | 14 | $8.18 | |
| 82962 | <1% | 180 | $6.46 | |
| 86901 | <1% | 128 | $2.04 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 759 | $1.76 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 103 | $1.30 |
| 36416 | 0% | 176 | $0.00 | |
| 86592 | 0% | 39 | $0.00 | |
| 82043 | 0% | 60 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 52 | $0.00 |
| 80320 | 0% | 91 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 52 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 51 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 31 | $0.00 |
| 86900 | 0% | 63 | $0.00 | |
| 83540 | 0% | 86 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 140 | $0.00 |
| 85007 | 0% | 41 | $0.00 | |
| 82570 | 0% | 99 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OP/AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.